Approvals by the China NMPA in 2023

被引：0
|
作者：
Xiecheng Zhi
Qiu Li
Liming Shao
机构：
来源：
Nature Reviews Drug Discovery | 2024年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：164 / 165
页数：1
相关论文
共 50 条
  • [1] Approvals by the China NMPA in 2023
    Zhi, Xiecheng
    Li, Qiu
    Shao, Liming
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (03) : 164 - 165
  • [2] Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA
    Lang Zheng
    Wenjing Wang
    Qiu Sun
    [J]. Signal Transduction and Targeted Therapy, 9
  • [3] Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA
    Zheng, Lang
    Wang, Wenjing
    Sun, Qiu
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [4] 2023 FDA approvals
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2024, 23 (2) : 88 - 95
  • [5] 2023 FDA approvals in gastroenterology and hepatology
    Kotsiliti, Eleni
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (04) : 219 - 219
  • [6] Cancer drug approvals and setbacks in 2023
    Elie Dolgin
    [J]. Nature Cancer, 2023, 4 (12) : 1612 - 1614
  • [7] 2023 FDA approvals in gastroenterology and hepatology
    Eleni Kotsiliti
    [J]. Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 219 - 219
  • [8] 2023 in review: FDA approvals of new medicines
    Kinch, Michael S.
    Kraft, Zachary
    Schwartz, Tyler
    [J]. DRUG DISCOVERY TODAY, 2024, 29 (05)
  • [9] 2023 FDA approvals: unprecedented volume at moderate value
    Baedeker, Mathias
    Ringel, Michael S.
    Moeller, Clemens C.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (02) : 98 - 98
  • [10] 2023 FDA approvals: unprecedented volume at moderate value
    Mathias Baedeker
    Michael S. Ringel
    Clemens C. Möller
    [J]. Nature Reviews Drug Discovery, 2024, 23 : 98 - 98
12345